Beximco Pharmaceuticals Limited (DSE:BXPHARMA)
Bangladesh · Delayed Price · Currency is BDT 111.90
-2.90 (-2.53%)
At close: Nov 3, 2025
Beximco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| 46,341 | 44,392 | 39,267 | 34,669 | 29,494 | 25,612 | Upgrade | |
Revenue Growth (YoY) | 11.26% | 13.05% | 13.26% | 17.55% | 15.16% | 12.25% | Upgrade |
Cost of Revenue | 25,757 | 24,989 | 22,164 | 18,989 | 15,677 | 13,787 | Upgrade |
Gross Profit | 20,584 | 19,403 | 17,102 | 15,681 | 13,816 | 11,825 | Upgrade |
Selling, General & Admin | 11,784 | 11,112 | 10,200 | 9,101 | 7,470 | 6,451 | Upgrade |
Operating Expenses | 11,784 | 11,112 | 10,200 | 9,101 | 7,470 | 6,451 | Upgrade |
Operating Income | 8,801 | 8,291 | 6,902 | 6,580 | 6,346 | 5,374 | Upgrade |
Interest Expense | -1,037 | -1,121 | -1,242 | -925.6 | -805.87 | -983.2 | Upgrade |
Interest & Investment Income | 37.39 | 17.08 | 7.46 | 5.07 | 3.32 | 21.84 | Upgrade |
Currency Exchange Gain (Loss) | 142.74 | 8.9 | 66.94 | 50.12 | -3.72 | 13.2 | Upgrade |
Other Non Operating Income (Expenses) | 261.2 | 311.17 | 314.3 | 402.75 | 298.91 | 261.72 | Upgrade |
EBT Excluding Unusual Items | 8,205 | 7,507 | 6,049 | 6,112 | 5,839 | 4,687 | Upgrade |
Merger & Restructuring Charges | - | - | - | -57.3 | -18.21 | - | Upgrade |
Gain (Loss) on Sale of Assets | 7.3 | 16.38 | 13.82 | 12.62 | 3.96 | -33.8 | Upgrade |
Other Unusual Items | 2.4 | 2.4 | 6.1 | 619.47 | 552.99 | - | Upgrade |
Pretax Income | 8,214 | 7,525 | 6,069 | 6,687 | 6,378 | 4,653 | Upgrade |
Income Tax Expense | 1,821 | 1,659 | 1,544 | 1,688 | 1,212 | 1,109 | Upgrade |
Earnings From Continuing Operations | 6,394 | 5,867 | 4,524 | 4,999 | 5,166 | 3,544 | Upgrade |
Minority Interest in Earnings | -40.09 | -37.24 | 89.6 | 124.51 | -38.06 | -29.8 | Upgrade |
Net Income | 6,354 | 5,830 | 4,614 | 5,123 | 5,128 | 3,515 | Upgrade |
Net Income to Common | 6,354 | 5,830 | 4,614 | 5,123 | 5,128 | 3,515 | Upgrade |
Net Income Growth | 29.23% | 26.34% | -9.94% | -0.09% | 45.89% | 15.87% | Upgrade |
Shares Outstanding (Basic) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade |
Shares Outstanding (Diluted) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade |
EPS (Basic) | 14.24 | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | Upgrade |
EPS (Diluted) | 14.24 | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | Upgrade |
EPS Growth | 29.23% | 26.34% | -9.94% | -0.09% | 45.89% | 15.87% | Upgrade |
Free Cash Flow | 4,095 | 6,371 | 3,674 | 2,399 | 3,503 | 3,299 | Upgrade |
Free Cash Flow Per Share | 9.18 | 14.28 | 8.24 | 5.38 | 7.85 | 7.39 | Upgrade |
Dividend Per Share | 4.000 | 4.000 | 3.500 | 3.500 | 3.500 | 1.364 | Upgrade |
Dividend Growth | 14.29% | 14.29% | - | - | 156.67% | - | Upgrade |
Gross Margin | 44.42% | 43.71% | 43.55% | 45.23% | 46.84% | 46.17% | Upgrade |
Operating Margin | 18.99% | 18.68% | 17.58% | 18.98% | 21.52% | 20.98% | Upgrade |
Profit Margin | 13.71% | 13.13% | 11.75% | 14.78% | 17.39% | 13.72% | Upgrade |
Free Cash Flow Margin | 8.84% | 14.35% | 9.36% | 6.92% | 11.88% | 12.88% | Upgrade |
EBITDA | 10,506 | 9,974 | 8,962 | 8,247 | 7,460 | 6,488 | Upgrade |
EBITDA Margin | 22.67% | 22.47% | 22.82% | 23.79% | 25.30% | 25.33% | Upgrade |
D&A For EBITDA | 1,706 | 1,684 | 2,061 | 1,667 | 1,114 | 1,114 | Upgrade |
EBIT | 8,801 | 8,291 | 6,902 | 6,580 | 6,346 | 5,374 | Upgrade |
EBIT Margin | 18.99% | 18.68% | 17.58% | 18.98% | 21.52% | 20.98% | Upgrade |
Effective Tax Rate | 22.17% | 22.04% | 25.45% | 25.25% | 19.00% | 23.83% | Upgrade |
Advertising Expenses | - | 241.76 | 212.23 | 196.72 | 160 | 140.88 | Upgrade |
Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.